Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 30
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Kyverna Therapeutics Inc
KYTX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$5.71
-0.14
-2.39%
Últ. Act.: Oct 30, 11:28 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Kyverna Therapeutics Financials
Kyverna Therapeutics (KYTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Benzinga Newsdesk
PRO
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
Benzinga Newsdesk
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?
Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.
Mohd Haider
PRO
Kyverna Therapeutics Q4 EPS $(0.80) Beats $(0.85) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.85) by 5.66 percent. This is a 8.11 percent decrease over losses of $(0.74) per share
Benzinga Newsdesk
Crude Oil Rises Over 1%; General Mills Earnings Top Views
Avi Kapoor
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
Avi Kapoor
